BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Black Diamond Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.81+0.09 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $103.83M
- P/E (TTM)
- –
- Dividend yield
- –
Black Diamond Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Market Cap | $103.99M | $166.30M |
| Enterprise Value | -$6.51M | $87.12M |
| PB Ratio | 1.08 | 2.03 |
| P/TBV Ratio | 1.08 | 2.31 |
Income (trailing twelve months)
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Operating Income | -$51.90M | -$21.49M |
| Net Income | -$42.56M | -$22.46M |
| EBITDA | -$51.90M | -$17.14M |
| EPS (Diluted) | -$0.74 | -$0.83 |
Returns
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -37.2% | -53.2% |
| Return on Assets (ROA) | -29.2% | -41.0% |
| Return on Capital Employed (ROCE) | -47.5% | -38.0% |
Growth
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 6.01% |
| Net Income Growth (YoY) | -394.7% | -37.7% |
| EPS Growth (YoY) | -421.7% | -29.2% |
Balance sheet
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $110.51M | $62.64M |
| Net Cash (Debt) | $110.51M | $15.77M |
| Net Cash Per Share | $1.92 | $0.66 |
| Equity (Book Value) | $96.09M | $48.61M |
| Book Value Per Share | $1.67 | $1.36 |
| Tangible Book Value | $96.09M | $23.01M |
| Working Capital | $99.55M | $75.09M |
Financial position
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.28 | 3.30 |
| Quick Ratio | 6.98 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$32.84M | -$12.39M |
Efficiency
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$2.03M | -$705.27K |
| Employee Count | 21 | 74 |
Dividends and yields
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -40.9% | -22.8% |
Shares
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 57,453,700 | 58,139,000 |
| Shares Change (YoY) | 0.76% | 11.1% |
| Shares Change (QoQ) | 0.25% | 0.54% |
| Float | 52,212,100 | 49,154,900 |
| Shares Held by Insiders | 9.12% | 11.6% |
| Shares Held by Institutions | 61.0% | 59.4% |
Scores
| Measure | Black Diamond Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.67 | -0.27 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Black Diamond Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.